Be Prepared to Treat Scurvy in Critically Ill Patients with ASCOR®
If your critically ill patients who are unable to take oral Vitamin C show signs and symptoms of scurvy, prescribe ASCOR®, the only FDA-approved ascorbic acid injection.
Click here to learn more about the signs and symptoms of scurvy
ASCOR® is vitamin C indicated for the short term (up to 1 week) treatment of
scurvy in adult and pediatric patients age 5 months and older for whom oral
administration is not possible, insufficient or contraindicated.
Limitations of Use:
ASCOR® is not indicated for treatment of vitamin C deficiency
that is not associated with signs and symptoms of scurvy.
Contraindications: None.
Administration site reactions include pain and swelling.
ASCOR® should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR® may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache.
Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid. ASCOR® is not indicated for prolonged administration. The maximum recommended duration is one week.
In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred.
Ascorbic acid may interfere with laboratory tests based
on oxidation-reduction reactions, including blood and
urine glucose testing, nitrite and bilirubin levels, and
leucocyte count testing. If possible, laboratory tests based
on oxidation-reduction reactions should be delayed until
24 hours after infusion of ASCOR®.
Please see accompanying Full Prescribing Information for ASCOR®.
The information contained in this section of the site is intended for U.S. healthcare professionals only.